SCHEMBL6302572

SCHEMBL6302572

Cc1cc2cc(Nc3ccnc4cc(C(=O)N5CCC(N)C5)sc34)ccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
EGFR P00533 12/20 0.49
FLT1 P17948 12/20 0.49
KDR P35968 3/20 0.39
MET P08581 1/20 0.38
SYK P43405 2/20 0.37
ROCK1 Q13464 1/20 0.37
VCP P55072 1/20 0.37
ROCK2 O75116 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6628355 1.00 EGFR (0.49) EGFRFLT1KDRMETSYK
SCHEMBL6302384 0.92 FLT1 (0.51) EGFRFLT1KDRMETSYK
SCHEMBL6309330 0.92 FLT1 (0.51) EGFRFLT1KDRMETSYK
SCHEMBL6302403 0.92 FLT1 (0.51) EGFRFLT1KDRMETSYK
SCHEMBL6302480 0.90 EGFR (0.49) EGFRFLT1KDRMETSYK
SCHEMBL6625751 0.90 EGFR (0.49) EGFRFLT1KDRMETSYK
SCHEMBL6302469 0.90 EGFR (0.49) EGFRFLT1KDRMETSYK
SCHEMBL6303870 0.90 EGFR (0.49) EGFRFLT1KDRMETSYK
SCHEMBL6301850 0.90 FLT1 (0.49) EGFRFLT1KDRMETSYK
SCHEMBL6301857 0.90 FLT1 (0.49) EGFRFLT1KDRMETSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6964961-B2 Thiophene derivatives useful as anticancer agents PFIZER INC (US) 2005-11-15 US claimed
EP-1287001-B1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2004-09-29 EP claimed
EP-1287001-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2003-03-05 EP claimed
US-20020042409-A1 Thiophene derivatives useful as anticancer agents PFIZER PRODUCTS INC. 2002-04-11 US claimed
WO-2001094353-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2001-12-13 WO claimed
US-6964961-B2 Thiophene derivatives useful as anticancer agents PFIZER INC (US) 2005-11-15 US disclosed
EP-1287001-B1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2004-09-29 EP disclosed
EP-1287001-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2003-03-05 EP disclosed
US-20020042409-A1 Thiophene derivatives useful as anticancer agents PFIZER PRODUCTS INC. 2002-04-11 US disclosed
WO-2001094353-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042409-A1 Thiophene derivatives useful as anticancer agents TP53, RCC1, CCNA1 EGFR 532/4885FLT1 733/4885KDR 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.